Canada-based group Breathtec Biomedical has announced it has acquired Nash Pharmaceuticals, another Canadian company with a pipeline of products still undergoing clinical trials in patients with Non-Alcoholic Steatohepatitis (NASH). NASH is a pathology spreading at an increasing rate, especially in the US, where it affects 15 million individuals.
NASH therapies have created a business growing at an unrivaled rate: it was worth as little as $618m in 2016, but it is expected to reach $25bn before 2026. The firms focusing the most on these therapies include Intercept Pharmaceutical, Madrigal Pharmaceuticals and Israel-based Galmed.
Breathtec’s shares have risen 4.7% after the announcement.